Abstract P5-16-21: The association of higher tumor HER2 load with treatment response to neoadjuvant therapy in HER2 positive breast cancer patients

Conclusion: Together these clinical and laboratory data suggests that TIMP-4 could be a prognostic as well as a predictive marker. Our preliminary clinical data indicates that TIMP-4 might be a more reliable marker for recurrence/progression than CA15-3. Also, our cell and animal studies indicate that TIMP-4 could be therapeutic target for TNBC and HER2-positive breast cancer patients that test positive for this marker. Thus providing a targeted therapy for TNBC patients and HER2-positive patients that do not have full clinical benefit of HER2-targeted therapies alone.Citation Format: Lillemoe TJ, Susnik B, Grimm E, Kang S-HL, Swenson KK, Krueger JL, Finkelstein MJ, Tsai ML. The association of higher tumor HER2 load with treatment response to neoadjuvant therapy in HER2 positive breast cancer patients [abstract]. In: Proceedings of the Thirty-Ninth Annual CTRC-AACR San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-16-21.

Source: Cancer Research - February 13, 2017 Category: Cancer & Oncology Authors: TJ Lillemoe, B Susnik, E Grimm, S-HL Kang, KK Swenson, JL Krueger, MJ Finkelstein, ML Tsai Tags: Poster Session Abstracts Source Type: research